Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

v3.22.2
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jan. 28, 2022
Oct. 06, 2021
Jun. 30, 2022
Dec. 31, 2021
Agreements        
Long-term royalty and commercial payment receivables     $ 66,575 $ 69,075
Contingent consideration under RPAs and CPPAs     3,075 8,075
Impairment of long-term royalty receivable     0 0
Affitech | Commercial Payment Purchase Agreement        
Agreements        
Upfront payment   $ 6,000    
Payments eligible to receive (as a percent) 0.50% 0.50%    
Commercial payment receivable term 10 years 10 years    
Maximum additional payments upon achievement of regulatory and sales milestones $ 3,000 $ 20,000    
Long-term royalty and commercial payment receivables   14,000    
Maximum payable on regulatory milestone   8,000    
Maximum payable on sales milestone   12,000    
Milestone payment 5,000      
Maximum payable on regulatory milestone, Additional amount 3,000      
Maximum payable on sales milestone, Additional amount $ 12,000      
Impairment of long-term royalty receivable     0 0
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones        
Agreements        
Contingent consideration under RPAs and CPPAs   $ 8,000 3,000 $ 8,000
Affitech | Commercial Payment Purchase Agreement | Sales milestones        
Agreements        
Contingent consideration under RPAs and CPPAs     $ 0